Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2

During development of the vertebrate vascular system essential signals are transduced via protein-tyrosine phosphorylation. Null-mutations of receptor-tyrosine kinase (RTK) genes expressed in endothelial cells (ECs) display early lethal vascular phenotypes. We aimed to identify endothelial protein-tyrosine phosphatases (PTPs), which should have similar importance in EC-biology. A murine receptor-type PTP was identified by a degenerated PCR cloning approach from endothelial cells (VE-PTP). By in situ hybridization this phosphatase was found to be specifically expressed in vascular ECs throughout mouse development. In experiments using GST-fusion proteins, as well as in transient transfections, trapping mutants of VE-PTP co-precipitated with the Angiopoietin receptor Tie-2, but not with the Vascular Endothelial Growth Factor receptor 2 (VEGFR-2/Flk-1). In addition, VE-PTP dephosphorylates Tie-2 but not VEGFR-2. We conclude that VE-PTP is a Tie-2 specific phosphatase expressed in ECs, and VE-PTP phosphatase activity serves to specifically modulate Angiopoietin/Tie-2 function. Based on its potential role as a regulator of blood vessel morphogenesis and maintainance, VE-PTP is a candidate gene for inherited vascular malformations similar to the Tie-2 gene.

Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro

Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, alpha8 integrin. HC11 cells derived from normal mammary epithelium do not express alpha8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express alpha8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-beta1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38MAPK and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-alpha in tenascin-W expression was also examined. TNF-alpha induced the expression of both tenascin-W and tenascin-C, and this induction was p38MAPK- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.

Die Entwicklung und Implementierung einer neuen staatlichen Schlussprüfung Humanmedizin am Beispiel Schweiz – Ergebnisse und Daten zur Prüfungsqualität der ersten 2 Kohorten sowie Überlegungen zur Qualitätssicherung und zur Weiterentwicklung der Prüfung

Hintergrund: Im Rahmen des neuen nationalen Medizinalberufegesetzes [http://www.admin.ch/ch/d/as/2007/4031.pdf], [http://www.bag.admin.ch/themen/berufe/07918/07919/index.html], der Entwicklung hin zu Kompetenz-basierten Curricula [1] und der Einführung der Bologna-Reform in den medizinischen Studiengängen [2] wurde in der Schweiz eine neue eidgenössische Schlussprüfung Humanmedizin unter Aufsicht des Bundes und in Zusammenarbeit mit den medizinischen Fakultäten in zwei Sprachen (D/F) entwickelt und 2011 erstmals durchgeführt. Projektbeschreibung: Im vorliegenden Beitrag werden die Rahmenbedingungen für die Implementierung aufgezeigt und die Entwicklung der Gesamtprüfung als Pass/Fail-Prüfung einschliesslich ihrer 2 Einzelprüfungen beschrieben. Die 1. Einzelprüfung besteht aus einer schriftlichen Prüfung (MCQ) an 2 Prüfungstagen zu je 4.5 h mit je 150 interdisziplinären, taxonomisch auf Anwendungswissen ausgerichteten Fragen. Die 2. Einzelprüfung umfasst eine strukturierte, klinisch-praktische CS-Prüfung (OSCE) mit insgesamt 12 Rotationsposten über je 13 min Dauer und je 2 min Rotationszeit zwischen den Posten. Zur Qualitätssicherung wurden zahlreiche Massnahmen ergriffen wie z.B. die Schulung der standardisierten Patienten anhand zentraler Standardisierungsvorlagen. Der Gesamtblueprint ist abgestimmt auf den Schweizer Lernzielkatalog Humanmedizin [http://sclo.smifk.ch] und beinhaltet die 2 Hauptdimensionen „General Objectives/CanMed Roles“ und „Problems as Starting Points“. Ergebnisse: Die Prüfung wurde an allen 5 Standorten 2011 und 2012 erfolgreich durchgeführt. Die Prüfungsresultate der ersten 2 Kohorten differenziert nach Gesamtprüfung und Einzelprüfungen zeigen in etwa die erwarteten Werte hinsichtlich der Bestehensquote. Die Metadaten zur Prüfungsqualität zeigen für beide Jahre, dass die angestrebte Messzuverlässigkeit der Prüfung mit einem Cronbach Alpha als Mass für die Reliabilität von im Mittel α=0.9 für die MCQ Einzelprüfung und von im Mittel α>0.8 für die CS-Einzelprüfung erreicht wurde. Diskussion und Schlussfolgerungen: Basierend auf den Erfahrungen und Daten der ersten 2 Prüfungskohorten kann gesagt werden, dass die Implementierung einer neuen nationalen Prüfung, die neben der neu ausgerichteten MCQ-Einzelprüfung erstmals mit einem strukturierten, objektivierbaren und national standardisierten Instrument klinische Fähigkeiten und Fertigkeiten misst, grundsätzlich gelungen ist. In diesem Kontext muss die Relevanz der intensiven Koordination und Abstimmung von der Gesetzgebung und den Verordnungsvorgaben bis hin zum Lernzielkatalog und dem korrespondierenden Gesamtblueprint der Prüfung hervorgehoben werden. Bezüglich der zukünftigen Entwicklung werden Aspekte der Qualitätssicherung und der Weiterentwicklung der Gesamtprüfung auch im Sinne von ergänzenden Prüfungsformaten diskutiert werden.

Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.

INTRODUCTION: Once metastasis has occurred, the possibility of completely curing breast cancer is unlikely, particularly for the 30 to 40% of cancers overexpressing the gene for HER2/neu. A vaccine targeting p185, the protein product of the HER2/neu gene, could have therapeutic application by controlling the growth and metastasis of highly aggressive HER2/neu+ cells. The purpose of this study was to determine the effectiveness of two gene vaccines targeting HER2/neu in preventive and therapeutic tumor models. METHODS: The mouse breast cancer cell line A2L2, which expresses the gene for rat HER2/neu and hence p185, was injected into the mammary fat pad of mice as a model of solid tumor growth or was injected intravenously as a model of lung metastasis. SINCP-neu, a plasmid containing Sindbis virus genes and the gene for rat HER2/neu, and Adeno-neu, an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu, were tested as preventive and therapeutic vaccines. RESULTS: Vaccination with SINCP-neu or Adeno-neu before tumor challenge with A2L2 cells significantly inhibited the growth of the cells injected into the mammary fat or intravenously. Vaccination 2 days after tumor challenge with either vaccine was ineffective in both tumor models. However, therapeutic vaccination in a prime-boost protocol with SINCP-neu followed by Adeno-neu significantly prolonged the overall survival rate of mice injected intravenously with the tumor cells. Naive mice vaccinated using the same prime-boost protocol demonstrated a strong serum immunoglobulin G response and p185-specific cellular immunity, as shown by the results of ELISPOT (enzyme-linked immunospot) analysis for IFNgamma. CONCLUSION: We report herein that vaccination of mice with a plasmid gene vaccine and an adenovirus gene vaccine, each containing the gene for HER2/neu, prevented growth of a HER2/neu-expressing breast cancer cell line injected into the mammary fat pad or intravenously. Sequential administration of the vaccines in a prime-boost protocol was therapeutically effective when tumor cells were injected intravenously before the vaccination. The vaccines induced high levels of both cellular and humoral immunity as determined by in vitro assessment. These findings indicate that clinical evaluation of these vaccines, particularly when used sequentially in a prime-boost protocol, is justified.

Role of germ line p53 mutations in aneuploidy and immortalization of dermal fibroblasts from Li-Fraumeni cancer patients

Pedigree analysis of certain families with a high incidence of tumors suggests a genetic predisposition to cancer. Li and Fraumeni described a familial cancer syndrome that is characterized by multiple primary tumors, early age of onset, and marked variation in tumor type. Williams and Strong (1) demonstrated that at least 7% of childhood soft tissue sarcoma patients had family histories that is readily explained by a highly penetrant autosomal dominant gene. To characterize the mechanism for genetic predisposition to many tumor types in these families, we have studied genetic alterations in fibroblasts, a target tissue from patients with the Li-Fraumeni Syndrome (LFS).^ We have observed spontaneous changes in initially normal dermal fibroblasts from LFS patients as they are cultured in vitro. The cells acquire an altered morphology, chromosomal anomalies, and anchorage-independent growth. This aberrant behavior of fibroblasts from LFS patients had never been observed in fibroblasts from normal donors. In addition to these phenotypic alterations, patient fibroblasts spontaneously immortalize by 50 population doublings (pd) in culture; unlike controls that remain normal and senesce by 30-35 (2). At 50 pd, immortal fibroblasts from two patients were found to be susceptible to tumorigenic transformation by an activated T24 H-ras oncogene (3). Approximately 80% of the oncogene expressing transfectants were capable of forming tumors in nude mice within 2-3 weeks. p53 has been previously associated with immortalization of cells in culture and cooperation with ras in transfection assays. Therefore, patients' fibroblast and lymphocyte derived DNA was tested for point mutations in p53. It was shown that LFS patients inherited certain point mutations in one of the two p53 alleles (4). Further studies on the above LFS immortal fibroblasts have demonstrated loss of the remaining p53 allele concomitant with escape from senescence. While the loss of the second allele correlates with immortalization it is not sufficient to transformation by an activated H-ras or N-ras oncogene. These immortal fibroblasts are resistant to tumorigenic transformation by v-abl, v-src, c-neu or v-mos oncogene; implying that additional steps are required in the tumorigenic progression of LFS patients' fibroblasts.^ References. (1) Williams et al., J. Natl. Cancer Inst. 79:1213, 1987. (2) Bischoff et al., Cancer Res. 50:7979, 1990. (3) Bischoff et al., Oncogene 6:183, 1991. (4) Malkin et al., Science 250:1233, 1990. ^

The role of BCL-2 in regulation of apoptosis susceptibility by modulation of glutathione

The role of oxidative stress and apoptosis has recently been recognized as an important determinant in the development of a variety of diseases known to man. The oncogene BCL-2 is known to regulate sensitivity to induction of apoptosis and appears to function in an antioxidant pathway by regulating glutathione. We have investigated various steps in the oxidative stress cascade to determine possible sites of action for BCL-2. The fluorescent probes H2DCFDA, dihydroethidium and cis-parinaric acid were used to quantitate generation of peroxides, superoxide and lipid peroxidation, respectively. While each of these agents was able to detect substantial increases in oxidative stress following exposure of cells to ionizing radiation, there was no significant difference between cells expressing high or low levels of BCL-2. Investigation of mitochondrial dysfunction during apoptosis revealed a possible site of bcl-2 intervention, but, analysis of kinetic events occurring during apoptosis suggested that the observed effect is not in the direct apoptotic effector pathway. When glutathione was studied, localization to the nucleus was observed in cells overexpressing BCL-2 that did not occur in cells lacking BCL-2. Additionally, nuclear accumulation of glutathione was sufficient to block granzyme b-mediated nuclear DNA fragmentation, poly (ADP-ribose) polymerase cleavage and caspase activity suggesting that nuclear accumulation of glutathione via a bcl-2 dependent process is functionally relevant to suppression of apoptosis. Thus, a model system emerges where BCL-2 is able to regulate a cell's ability to prevent apoptosis by modifying the cell's antioxidant systems at the organelle level to compensate for oxidative stresses placed upon it. ^

Von der Bewegung her denken: Migration als soziale Bewegung im eigentlichen Wortsinne

Ein Grund der Krise der Migrationsforschung liegt daran, dass ihre vorherrschende Blickrichtung vom Staat aus auf Migration gerichtet ist. Während der Staat naturalisiert wird, erscheint Migration als die störende Bewegung. Exakt diese Kritik ist in der Losung „We didn’t cross the border, the border crossed us!“ des Immigrant Rights Movement aus den USA enthalten. Nur eine Umkehrung der Perspektive kann aus der Sackgasse führen, in welche Konzepte wie „Integration“ geführt haben, indem Fragen neu gestellt werden können: Was passiert, wenn Effekte von Staat und Staatlichkeit in die Bewegung der Migration eingeschrieben werden? Prototyp dieser Einschreibung ist die Grenze, die sich aber nicht auf deren geopolitische Manifestation beschränkt, sondern verschiedenste Grenzkontrollpraktiken (Datenbanken, Migrationsprogramme und -verträge zwischen Staaten, Rückübernahmeabkommen von abgewiesenen Asylsuchenden) umfasst, die oftmals deterritorialisiert und relokalisert sind. Ausgehend von der Kritik des Methodologischen Nationalismus skizziert der Beitrag, wie ein Ansatz der Migrationsforschung aussehen könnte, der von der Bewegung aus denkt, wie es etwa in der Idee der Autonomie der Migration angedacht ist. Am Beispiel des laufenden Projektes „How Does Border Occur?“, das unter anderem die sogenannt freiwilligen Rückkehrprogramme für tunesische Migrantinnen untersucht, stellt der Beitrag schliesslich zur Diskussion, wie ein solches Forschungsprogramm konkret aussehen könnte.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

BACKGROUND Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial. METHODS The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were disease-free 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of 1 year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.gov, number NCT00045032. FINDINGS We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0·99, 95% CI 0·85-1·14, p=0·86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group (342 [20·4%] vs 275 [16·3%] grade 3-4 adverse events, and 120 [7·2%] vs 69 [4·1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0·76 (95% CI 0·67-0·86, p<0·0001) for disease-free survival and 0·76 (0·65-0·88, p=0·0005) for overall survival, despite crossover of 884 (52%) patients from the observation group to trastuzumab therapy. INTERPRETATION 2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer. 1 year of treatment provides a significant disease-free and overall survival benefit compared with observation and remains the standard of care. FUNDING F Hoffmann-La Roche (Roche).

Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2

Bcl-2 oncogene expression plays a role in the establishment of persistent viral infection by blocking virus-induced apoptosis. This might be achieved by preventing virus-induced activation of caspase-3, an IL-1beta-converting enzyme (ICE)-like cysteine protease that has been implicated in the death effector phase of apoptosis. Contrary to this model, we show that three cell types highly overexpressing functional Bcl-2 displayed caspase-3 activation and underwent apoptosis in response to infection with alphaviruses Semliki Forest and Sindbis as efficiently as vector control counterparts. In all three cell types, overexpressed 26 kDa Bcl-2 was cleaved into a 23 kDa protein. Antibody epitope mapping revealed that cleavage occurred at one or two target sites for caspases within the amino acid region YEWD31 (downward arrow) AGD34 (downward arrow) A, removing the N-terminal BH4 region known to be essential for the death-protective activity of Bcl-2. Preincubation of cells with the caspase inhibitor Z-VAD prevented Bcl-2 cleavage and partially restored the protective activity of Bcl-2 against virus-induced apoptosis. Moreover, a murine Bcl-2 mutant having Asp31, Asp34 and Asp36 substituted by Glu was resistant to proteolytic cleavage and abrogated apoptosis following virus infection. These findings indicate that alphaviruses can trigger a caspase-mediated inactivation of Bcl-2 in order to evade the death protection imposed by this survival factor.

Alterthümer der Prager Josefstadt : israelitischer Friedhof, Alt-Neu-Schule und andere Synagogen

hrsg. von David J. Podiebrad. Verfasst ... von Benedict Foges

Alterthümer der Prager Josefstadt, israelitischer Friedhof, Alt-Neu-Schule und andere Synagogen ; ... zum Theile nach gesammelten Daten und erworbenen Manuscripten des Herrn David J. Podiebrad ...

verf. von Benedikt Foges

Alterthümer der Prager Josefstadt, israelitischer Friedhof, Alt-Neu-Schule und andere Synagogen : zum Theile nach gesammelten Daten und erworbenen Manuscripten des Herausgebers verfaßt

von Benedikt Foges. Hrsg. von David J Podiebrad